GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (LTS:0A9E) » Definitions » Price-to-Free-Cash-Flow

CureVac NV (LTS:0A9E) Price-to-Free-Cash-Flow : 5.63 (As of May. 24, 2025)


View and export this data going back to 2021. Start your Free Trial

What is CureVac NV Price-to-Free-Cash-Flow?

As of today (2025-05-24), CureVac NV's share price is $4.181. CureVac NV's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.74. Hence, CureVac NV's Price-to-Free-Cash-Flow Ratio for today is 5.63.

The historical rank and industry rank for CureVac NV's Price-to-Free-Cash-Flow or its related term are showing as below:

LTS:0A9E' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.49   Med: 6.05   Max: 9.36
Current: 5.51

During the past 7 years, CureVac NV's highest Price-to-Free-Cash-Flow Ratio was 9.36. The lowest was 3.49. And the median was 6.05.

LTS:0A9E's Price-to-Free-Cash-Flow is ranked better than
89.73% of 224 companies
in the Biotechnology industry
Industry Median: 31.2 vs LTS:0A9E: 5.51

CureVac NV's Free Cash Flow per Share for the three months ended in Mar. 2025 was $-0.20. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.74.

During the past 7 years, CureVac NV's highest 3-Year average Free Cash Flow per Share Growth Rate was -50.30% per year. The lowest was -108.90% per year. And the median was -79.60% per year.


CureVac NV Price-to-Free-Cash-Flow Historical Data

The historical data trend for CureVac NV's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Price-to-Free-Cash-Flow Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial 18.54 - - - 8.79

CureVac NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 6.00 8.79 3.73

Competitive Comparison of CureVac NV's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, CureVac NV's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CureVac NV's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CureVac NV's Price-to-Free-Cash-Flow falls into.


;
;

CureVac NV Price-to-Free-Cash-Flow Calculation

CureVac NV's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=4.181/0.742
=5.63

CureVac NV's Share Price of today is $4.181.
CureVac NV's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.74.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

CureVac NV  (LTS:0A9E) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


CureVac NV Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of CureVac NV's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV Business Description

Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

CureVac NV Headlines

No Headlines